MOTRIN IB Drug Patent Profile
Which patents cover Motrin Ib, and when can generic versions of Motrin Ib launch?
Motrin Ib is a drug marketed by Kenvue Brands and is included in two NDAs.
The generic ingredient in MOTRIN IB is ibuprofen. There is one drug master file entry for this compound. Two hundred and fifty-two suppliers are listed for this compound. Additional details are available on the ibuprofen profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Motrin Ib
A generic version of MOTRIN IB was approved as ibuprofen by CONTRACT PHARMACAL on October 15th, 1986.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for MOTRIN IB?
- What are the global sales for MOTRIN IB?
- What is Average Wholesale Price for MOTRIN IB?
Summary for MOTRIN IB
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 2 |
| Finished Product Suppliers / Packagers: | 3 |
| Raw Ingredient (Bulk) Api Vendors: | 1 |
| Clinical Trials: | 74 |
| Patent Applications: | 4,017 |
| What excipients (inactive ingredients) are in MOTRIN IB? | MOTRIN IB excipients list |
| DailyMed Link: | MOTRIN IB at DailyMed |
Recent Clinical Trials for MOTRIN IB
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| University of Miami | Phase 2 |
| Guangzhou Kangqi Medical Technology Co., LTD | Phase 1 |
| Weill Medical College of Cornell University | Phase 4 |
Pharmacology for MOTRIN IB
| Drug Class | Nonsteroidal Anti-inflammatory Drug |
| Mechanism of Action | Cyclooxygenase Inhibitors |
US Patents and Regulatory Information for MOTRIN IB
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Kenvue Brands | MOTRIN IB | ibuprofen | SUSPENSION;ORAL | 020516-002 | Jul 22, 2026 | OTC | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Kenvue Brands | MOTRIN IB | ibuprofen | TABLET;ORAL | 019012-003 | Dec 17, 1990 | OTC | Yes | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
EU/EMA Drug Approvals for MOTRIN IB
| Company | Drugname | Inn | Product Number / Indication | Status | Generic | Biosimilar | Orphan | Marketing Authorisation | Marketing Refusal |
|---|---|---|---|---|---|---|---|---|---|
| Recordati Rare Diseases | Pedea | ibuprofen | EMEA/H/C/000549Treatment of a haemodynamically significant patent ductus arteriosus in preterm newborn infants less than 34 weeks of gestational age. | Authorised | no | no | no | 2004-07-28 | |
| >Company | >Drugname | >Inn | >Product Number / Indication | >Status | >Generic | >Biosimilar | >Orphan | >Marketing Authorisation | >Marketing Refusal |
International Patents for MOTRIN IB
See the table below for patents covering MOTRIN IB around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Austria | 110259 | ⤷ Start Trial | |
| Australia | 5792690 | ⤷ Start Trial | |
| Australia | 635283 | ⤷ Start Trial | |
| Canada | 2019863 | SUSPENSION AQUEUSE PHARMACEUTIQUE POUR DES INGREDIENTS ACTIFS PHARMACEUTIQUES PEU HYDROSOLUBLES (AQUEOUS PHARMACEUTICAL SUSPENSION FOR SUBSTANTIALLY WATER INSOLUBLE PHARMACEUTICAL ACTIVES) | ⤷ Start Trial |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for MOTRIN IB
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1781277 | PA2024501 | Lithuania | ⤷ Start Trial | PRODUCT NAME: IBUPROFENO IR PARACETAMOLIO DERINYS; REGISTRATION NO/DATE: LT/1/23/5212/001-002 20230726 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2026 - 2027
NCE-1 Patent Challenge Dates 2026 - 2027
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2026, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch